Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback